USFDA completes GMP inspection at Lupin’s API manufacturing facility at Dabhasa

12 Apr 2024 Evaluate

United States Food and Drug Administration (USFDA) has completed a GMP Inspection of Lupin’s API manufacturing facility located at Dabhasa, India. The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations. This accomplishment underscores the company’s unwavering dedication to maintaining the highest standards of quality and compliance in all aspects of its operations. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

1645.00 7.45 (0.45%)
30-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1502.30
Dr. Reddys Lab 6198.90
Cipla 1402.20
Zydus Lifesciences 957.00
Lupin 1645.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.